Novavax, Inc. (NVAX)
-NasdaqGS 1.96 
0.02(1.01%) May 21, 4:00PM EDT
| Prev Close: | 1.98 |
|---|
| Open: | 1.99 |
|---|
| Bid: | 1.92 x 1000 |
|---|
| Ask: | 2.58 x 200 |
|---|
| 1y Target Est: | 4.21 |
|---|
| Beta: | 1.3 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 1.95 - 2.02 |
|---|
| 52wk Range: | 1.14 - 2.77 |
|---|
| Volume: | 710,234 |
|---|
| Avg Vol (3m): | 1,433,520 |
|---|
| Market Cap: | 296.37M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.23 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Will Influenza A H7N9 Generate Opportunities For Pharma?at Seeking Alpha(Tue, May 21)
- Flexion Therapeutics Names Frederick Driscoll Chief Financial OfficerPR Newswire(Mon, May 20)
- NOVAVAX INC FinancialsEDGAR Online Financials(Fri, May 17)
- 6 Superstars For Your Biotech Portfolio: John McCamantat Seeking Alpha(Fri, May 10)
- Novavax H7N9 VLP Influenza Vaccine Enters Animal TestingGlobeNewswire(Fri, May 10)
- NOVAVAX INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Novavax's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 7)
- NOVAVAX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue, May 7)
- Novavax Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Tue, May 7)
- Novavax Reports First-Quarter 2013 Financial ResultsGlobeNewswire(Tue, May 7)
- Q1 2013 Novavax Earnings Release - Before Market OpenCCBN(Tue, May 7)
- China's H7N9 Bird Flu And Novavaxat Seeking Alpha(Fri, May 3)
- In Development-Stage Biotechs, Success Comes Down to One Asset: Expert Analyst Boris Peaker Discusses the Competitive Biotechnology Environment with The Wall Street TranscriptWall Street Transcript(Wed, May 1)
- Hedge Funds Are Buying These 3 Biotech Small Caps Trading Below Lowest Target Priceat Seeking Alpha(Wed, May 1)
- Novavax CFO to resign effective May 17theflyonthewall.com(Mon, Apr 29)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 14.08 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.24 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.06 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases.
View More